Lumida
/REPL
⌘K
Replimune Group Inc

Replimune Group Inc

REPL
$10.23USD↑+7.46%+0.71 today

MARKET CAP

859.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$9 – $10

52W RANGE

$2
$13

AI Summary

Stalk
StalkMedium

REPL is in a Stage 2 advancing corrective reset within a long-term downtrend. Medium-term bias remains bullish on the Stage 2 higher-high/higher-low structure, but the recent rejection below the 9/21 EMAs makes short-term timing unfavorable. Under the Speculative strategy, execution is deferred and focused on pullbacks into the rising 50-day EMA and prior support zone for selective entry rather than chasing current weakness.

  • ↑Q4 cash of $483.8M (+15% YoY) provides runway for RP1 launch
  • ↑Up to 80% of ~13k US PD-1 nonresponders eligible for RP1 annually
  • ↓Fiscal net loss $247.3M highlights weak profitability and margin conversion
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Replimune Group (NASDAQ: REPL) is an innovative biotechnology company that focuses on developing oncolytic immunotherapies, particularly targeting advanced melanoma with its lead candidate, RP1. The company is positioned uniquely within the biotechnology landscape, capitalizing on the significant unmet medical needs of patients who have not responded to earlier treatments like anti-PD-1 therapies. With a strong cash position and comprehensive commercialization strategies, Replimune aims to fulfill a pivotal role in the evolving treatment of melanoma.

Bull says

  • ↑Q4 cash of $483.8M (+15% YoY) provides runway for RP1 launch
  • ↑Up to 80% of ~13k US PD-1 nonresponders eligible for RP1 annually
  • ↑Strong institutional backing and high 13F ownership signal investor confidence
  • ↑Breakthrough designation and July 22, 2025 PDUFA date target rapid FDA approval
  • ↑High liquidity, strong quant sentiment, and 0.46% dividend yield boost stability

Bear says

  • ↓Fiscal net loss $247.3M highlights weak profitability and margin conversion
  • ↓R&D expenses $189.4M YTD (Q4: $54M) heighten cash-burn concerns
  • ↓Short interest up 3.4% and negative technical momentum signal bearish sentiment
  • ↓Elevated leverage risk raises financial vulnerability amid ongoing losses
  • ↓Emerging therapies from BMY, AMGN, MRK threaten RP1 market share

Investment themes with REPL

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2025 · Mgmt. Guidance

Updated 07-17-2026bullish

Transcript signals

Bull points

  • We expect the trial to take a couple of years to complete enrollment given the study population and size of the study.
  • We believe RP1 will be well-positioned for most patients who progress on a PD-1-containing regimen based on the deep and durable response rates, as well as the safety profile demonstrated in our night registrational trials.
  • The commercial opportunity for RP1 to help improve the lives of those with advanced melanoma is considerable. We estimate approximately 13,000 patients progress on or after PD-1 treatment annual in the U.S. and about 80% of these patients would be eligible for RP1 distributed evenly across hospital and non-hospital settings.

Bear points

  • The company's net loss was $74.1 million for the fiscal fourth quarter, and $247.3 million for the fiscal year ended March 31, 2025, as compared to a net loss of $55.1 million for the fiscal fourth quarter and $215.8 million for the fiscal year ended March 31, 2024.
Read full transcript analysis ›